Date: 2016-05-24
Type of information: Private placement
Company: CEL-SCI Corporation (USA -VA)
Investors: undisclosed single healthcare dedicated institutional investor
Amount: $ 5 million
Funding type: private placement
Planned used: The net proceeds of the offering will be used for the ongoing Phase 3 study and general corporate purposes.
Others: * On May 24, 2016, CEL-SCI Corporation announced that it has closed its previously announced registered direct offering with a single healthcare dedicated institutional investor. The Company has received gross proceeds of $5 million. Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, acted as the exclusive placement agent in connection with the offering. * On May 18, 2016, CEL-SCI Corporation announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase approximately 10 million shares of its common stock and warrants exercisable for up to approximately 6.66 million shares of its common stock for gross proceeds of $5 million. The warrants will be exercisable six months following the date of issuance, will expire on the fifth anniversary of the initial exercise date and have an exercise price of $0.55 per share. The closing of the offering is expected to take place on or about May 20, 2016, subject to the satisfaction of customary closing conditions. Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, acted as the exclusive placement agent in connection with the offering.
Therapeutic area: Cancer - Oncology
